BridgeBio Pharma

YTD

ALL

Trade BridgeBio Pharma 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development.

CEO

Neil Kumar

CEONeil Kumar

Employees

839

Employees839

Headquarters

Palo Alto, California

HeadquartersPalo Alto, California

Founded

2015

Founded2015

Employees

839

Employees839

BBIO Key Statistics

Market cap

12.88B

Market cap12.88B

Price-Earnings ratio

-17.57

Price-Earnings ratio-17.57

Dividend yield

—

Dividend yield—

Average volume

3.39M

Average volume3.39M

High today

$68.47

High today$68.47

Low today

$65.46

Low today$65.46

Open price

$66.27

Open price$66.27

Volume

2.26M

Volume2.26M

52 Week high

$84.94

52 Week high$84.94

52 Week low

$28.33

52 Week low$28.33

Stock Snapshot

The current BridgeBio Pharma(BBIO) stock price is $66.61, with a market capitalization of 12.88B. The stock trades at a price-to-earnings (P/E) ratio of -17.57.

On 2026-03-01, BridgeBio Pharma(BBIO) stock moved within a range of $65.46 to $68.47. With shares now at $66.61, the stock is trading +1.8% above its intraday low and -2.7% below the session's peak.

Trading volume for BridgeBio Pharma(BBIO) stock has reached 2.26M, versus its average volume of 3.39M.

Over the past 52 weeks, BridgeBio Pharma(BBIO) stock has traded between a high of $84.94 and a low of $28.33.

BBIO News

Simply Wall St 22h

BridgeBio Pharma Sees Pivotal Shift As Late Stage Success Meets Attruby Sales

BridgeBio Pharma (NasdaqGS:BBIO) released positive top line Phase 3 data for Encaleret, BBP-418 and Infigratinib. The company reported strong commercial moment...

Simply Wall St 2d

What BridgeBio Pharma's Surging 2025 Revenue and Growing Losses Means For Shareholders

BridgeBio Pharma, Inc. has reported its fourth-quarter and full-year 2025 results, with Q4 revenue rising to US$154.18 million from US$5.88 million a year earli...

Nasdaq 3d

BBIO February 2027 Options Begin Trading

Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available today, for the February 2027 expiration. One of the key data points that goes...

Analyst ratings

96%

of 23 ratings

Buy

95.7%

Hold

4.3%

Sell

More BBIO News

Simply Wall St 4d

BridgeBio’s Infigratinib Data Reframes Growth Prospects In Rare Disease Franchise

BridgeBio Pharma (NasdaqGS:BBIO) reported positive Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia. The trial met its primary an...

People also own

Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Shopify

Viking Therapeutics

Taiwan Semiconductor Manu…

Trade Desk

Unity Software

Alibaba

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.